Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4181089 | 0.95 | IDO1 (0.58) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL27329 | 0.95 | IDO1 (0.58) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL1475480 | 0.93 | IDO1 (0.56) | IDO1CA12CA1CA2CA7 | |
| Methyl Alcohol SCHEMBL28311094 | 0.93 | IDO1 (0.56) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL1477048 | 0.93 | IDO1 (0.56) | IDO1CA12CA1CA2CA7 | |
| Methoxymethane SCHEMBL28284584 | 0.93 | IDO1 (0.56) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL15828875 | 0.88 | TAAR1 (0.59) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL8008449 | 0.88 | LTA4H (0.65) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL6285826 | 0.88 | MAOB (0.59) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL8993364 | 0.88 | LTA4H (0.65) | IDO1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3248969-B1 | PROCESS FOR THE PREPARATION OF N-[3-(AMINOMETHYL)OXETAN-3-YL]CARBAMATE INTERMEDIATES | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | claimed |
| EP-3658111-A1 | ACTIVE SUBSTANCE COMBINATIONS OF N-(4-AMINO-2-METHYLQUINOLINE-6-YL)-2-((4-ETHYLPHENOXY)METHYL)BENZAMIDE AND ONE OR MORE COSMETICALLY OR DERMATOLOGICALLY ACCEPTABLE AROMATIC SUBSTANCES | Beiersdorf AG (DE) | 2020-06-03 | — | — | EP | disclosed |
| US-8580728-B2 | Use of fragrance compositions for the prevention of the development of indole base malodours from fecal and urine based soils | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-11-12 | — | — | US | disclosed |
| EP-1884251-B1 | Use of fragrance compositions for restricting the formation of indole from faecal and urine based soils | TAKASAGO PERFUMERY CO LTD (JP) | 2013-08-28 | — | — | EP | disclosed |
| EP-2467125-A2 | PRODUCTS HAVING AN OLFACTORY EFFECT PROVEN BY A MEASURING METHOD FOR INFLUENCING THE PSYCHO-PHYSIOLOGICAL DISPOSITION | Kneipp-Werke Kneipp-Mittel-Zentrale GmbH & Co. KG (DE) | 2012-06-27 | — | — | EP | disclosed |
| US-7759370-B2 | Sphingosine-1-phosphate (SIP) receptor agonists | Praecis Pharmaceuticals (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100104525-A1 | USE OF FRAGRANCE COMPOSITIONS FOR THE PREVENTION OF THE DEVELOPMENT OF INDOLE BASE MALODOURS FROM FECAL AND URINE BASED SOILS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100016260-A1 | AGONISTS OF SPHINGOSINE-1 PHOSPHATE RECEPTOR (SLP) | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2046766-A1 | AGONISTS OF THE SPHINGOSINE- 1- PHOSPHATE RECEPTOR (SLP) | Praecis Pharmaceuticals Incorporated (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080070866-A1 | Chemical compounds | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080032912-A1 | Use of fragrance compositions for the prevention of the development of indole base malodours from fecal and urine based soils | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2008-02-07 | — | — | US | disclosed |
| WO-2008016674-A1 | AGONISTS OF THE SPHINGOSINE- 1- PHOSPHATE RECEPTOR (SLP) | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-1884251-A1 | Use of fragrance compositions for the prevention of the development of indole based malodours from faecal and urine based soils | Takasago International Corporation (JP) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007038524-A2 | COCRYSTALLIZATION METHODS | SSCI, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016260-A1 | AGONISTS OF SPHINGOSINE-1 PHOSPHATE RECEPTOR (SLP) | S1PR1, S1PR2, S1PR5 | IDO1 778/4885CA12 4797/4885CA1 4751/4885 |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | S1PR1, S1PR2, S1PR5 | IDO1 120/4885CA12 4878/4885CA1 4804/4885 |
| US-20080070866-A1 | Chemical compounds | S1PR1, S1PR2, S1PR5 | IDO1 217/4885CA12 4602/4885CA1 4684/4885 |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | CD4, ICOS, NFATC1 | IDO1 88/4885CA12 4536/4885CA1 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.